J Reconstr Microsurg 2013; 29(05): 341-346
DOI: 10.1055/s-0033-1343830
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Preclinical Efficacy of Slow-Release bFGF in Ischemia-Reperfusion Injury in a Dorsal Island Skin Flap Model

Yang Wang
1   Department of Plastic and Reconstructive Surgery, Nippon Medical School, Tokyo, Japan
,
Hakan Orbay
1   Department of Plastic and Reconstructive Surgery, Nippon Medical School, Tokyo, Japan
,
Chenyu Huang
1   Department of Plastic and Reconstructive Surgery, Nippon Medical School, Tokyo, Japan
,
Morikuni Tobita
2   Department of Plastic and Reconstructive Surgery, Juntendo University School of Medicine, Tokyo, Japan
,
Hiko Hyakusoku
1   Department of Plastic and Reconstructive Surgery, Nippon Medical School, Tokyo, Japan
,
Masaaki Myamoto
3   Division of Regenerative Medicine, Nippon Medical School, Tokyo, Japan
,
Yasuhiko Tabata
4   Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
,
Hiroshi Mizuno
2   Department of Plastic and Reconstructive Surgery, Juntendo University School of Medicine, Tokyo, Japan
› Institutsangaben
Weitere Informationen

Publikationsverlauf

27. Juli 2012

30. Dezember 2012

Publikationsdatum:
15. April 2013 (online)

Preview

Abstract

The effect of slow-release basic fibroblast growth factor (bFGF) on ischemia-reperfusion injury was examined using an island skin flap model in rats. Paired rectangular island skin flaps were elevated on the dorsum of 30 Fischer rats. The flaps were subjected to 6 hours of ischemia. Before reperfusion the flaps were injected with acidic gelatin hydrogel microspheres + phosphate-buffered saline (PBS) (group I), 20 μg slow-release bFGF + PBS (group II), 50 μg slow-release bFGF + PBS (group III), and 150 μg slow-release bFGF + PBS (group IV). The mean percent flap survival area and the average number of vessels detected by microangiography were significantly higher in group IV (p < 0.05) than in groups I, II, and III. The immunohistochemical staining for vasculogenic growth factors was quantitatively higher in group IV (p < 0.01). In conclusion, slow-release bFGF prevents ischemia-reperfusion injury by upregulating the secretion of vasculogenic growth factors.

Note

Drs. Wang Orbay shares co-first author.